PeopleBio reported provisional consolidated Q2 2026 revenue of 1,669 million KRW, up 159.6% from the previous quarter's 643 million KRW and 128% from 732 million KRW in the same period last year.
Operating loss decreased to 687 million KRW, a 53.5% improvement from a loss of 1,483 million KRW in Q1 2026 and a 65.2% reduction from a loss of 1,975 million KRW in Q2 2025.
These results are provisional based on internal consolidation under K-IFRS and have not been reviewed by external auditors; final figures may differ.
No capital transactions, dividend changes, or governance issues were disclosed alongside the earnings release.
[AI Summary]PeopleBio's Q2 provisional results show strong revenue growth and narrowing operating losses, but the company remains loss-making with limited internal cash generation. With no capital structure changes, near-term dilution risk is absent, but eventual funding needs for breakeven should be monitored.